Tech Company Financing Transactions
PreciThera Funding Round
Arix Bioscience, CTI Life Sciences Fund and Emerillon Capital participated in a $29 million Series A funding round for PreciThera. The round was recorded on 7/28/2017.
Transaction Overview
Company Name
Announced On
7/28/2017
Transaction Type
Venture Equity
Amount
$29,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds of the Series A financing will be used to develop novel molecules and to advance PreciThera's lead candidate through IND and into clinical studies with the goal to establish clinical proof of concept and identify a path to registration.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1010 Sherbrooke St. West 408
Montreal QC, H3A 2R7
Canada
Montreal QC, H3A 2R7
Canada
Phone
Website
Email Address
Overview
PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pierre Beauparlant
Chief Financial Officer
Michael Dixon
Chief Operating Officer
Philippe Crine
Chief Scientific Officer
Susan Schiavi
Browse more venture capital transactions:
Prev: 7/28/2017: Megacool venture capital transaction
Next: 7/28/2017: MultiMechanics venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs